

Review Article

Peripartum Cardiomyopathy (PPCM) – A Comprehensive Review.

Jayesh Trivedi¹, Virendra Kumar Goyal², Sohail³, Priya Kunwar⁴, Shubham Balki⁵, Keyur Soni⁵, Ayushya Pal Singh⁵, Sudeep Deswal⁵, Shweta Pandey⁵, Harjeet kaur⁵, Simran kajla⁵, Himanshu Yadav⁵, Raja Joshi⁵.

1. Professor Department of Internal Medicine Pacific Medical College & Hospital, Udaipur.
2. Professor & Head of Department of Internal Medicine Pacific Medical College & Hospital, Udaipur.
3. Assistant Professor, Department of Internal Medicine Pacific Medical College & Hospital, Udaipur.
4. Senior Resident, Department of Internal Medicine Pacific Medical College & Hospital, Udaipur.
5. Post Graduate Residents, Department of Internal Medicine Pacific Medical College & Hospital, Udaipur.

Abstract

Peripartum cardiomyopathy (PPCM) is an uncommon yet life-threatening form of heart failure occurring towards the end of pregnancy or in the months following delivery in women with no prior heart disease. It is characterized by left ventricular systolic dysfunction (often with an ejection fraction <45%) arising in the peripartum period without other identifiable causes. PPCM typically presents with symptoms of heart failure – such as dyspnea, orthopnea, edema, and fatigue – which can be mistaken for normal peripartum changes, leading to potential delays in diagnosis. The etiopathogenesis remains incompletely understood; proposed mechanisms include a “two-hit” model of pregnancy-induced hemodynamic stress or hormonal insult (e.g. cleavage of prolactin into cardiotoxic fragments) superimposed on an underlying genetic or microvascular vulnerability. Prompt diagnosis relies on a high index of suspicion and confirmation by echocardiography demonstrating reduced ejection fraction, alongside exclusion of other causes of cardiac failure. Management requires a multidisciplinary approach and is centered on guideline-directed heart failure therapy tailored to pregnancy and lactation, including beta-blockers, vasodilators, diuretics, and anticoagulation when indicated. In severe cases, advanced therapies such as bromocriptine (to halt prolactin release), mechanical circulatory support, or cardiac transplantation may be necessary. With timely treatment, the prognosis has improved: many patients experience substantial recovery of cardiac function within 6–12 months, though a subset suffer persistent cardiomyopathy or relapse with subsequent pregnancies. This review provides an in-depth overview of PPCM, including current insights into its epidemiology, pathophysiology, clinical presentation, diagnostic criteria, and state-of-the-art management strategies, with emphasis on recent guidelines and outcomes data relevant to specialist care.

INTRODUCTION

PPCM is an idiopathic form of dilated cardiomyopathy that presents as heart failure in last 1 month of pregnancy to 5 months of pregnancy. The Heart Failure Association of the ESC defines PPCM as “an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic dysfunction towards the end of pregnancy or in the months following delivery, where no other cause is found”. The diagnosis is confirmed by echocardiographic evidence of reduced left ventricular ejection fraction (LVEF), classically <45%, with or without ventricular dilation. PPCM must be notably different from other causes of peripartum dyspnea and heart failure, such as preeclampsia-related cardiac dysfunction, pulmonary embolism, or occult congenital or valvular disease.

Epidemiology

PPCM is relatively rare, but its incidence varies widely geographically. In the United States, estimates range from approximately 1 in 900 to 1 in 4,000 live births. Recent data suggest the incidence may be rising, possibly due to older maternal age, increased multifetal pregnancies (assisted reproduction), and greater awareness of the condition. Notably, there are pronounced racial and regional differences. African American women have roughly a four-fold higher risk of PPCM than white women. Although African Americans constitute <15% of the US population, they accounted for nearly half of PPCM cases in some cohorts. In contrast, Hispanic and Asian populations show lower incidence rates. Globally, incidence ranges from as high as 1 in 90–100 deliveries in parts of Nigeria to as low as 1 in 15,000–20,000 in Japan, underscoring potential genetic and environmental

***Corresponding Author:** Jayesh Trivedi, Professor Department of Internal Medicine Pacific Medical College & Hospital, Udaipur,

E-mail: drjvtrivedi@rediffmail.com.

Received: 18-April-2025, Manuscript No. TJOHT - 4774 ; **Editor Assigned:** 19-April-2025 ; **Reviewed:** 14-May-2025, QC No. TJOHT - 4774 ;

Published: 23-May-2025, **DOI:** 10.52338/tjoht.2025.4774

Citation: Jayesh Trivedi. Peripartum Cardiomyopathy (PPCM) – A Comprehensive Review. The Journal of Hypertension. 2025 May; 11(1). doi: 10.52338/tjoht.2025.4774.

Copyright © 2025 Jayesh Trivedi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

influences. PPCM also contributes significantly to maternal mortality; in the USA, it is estimated to cause around 10% of pregnancy-related deaths, with reported maternal mortality rates of ~6–10% in developed countries and higher (10–30% at 1–2 years) in certain developing regions.

Risk Factors

Several risk factors have been identified, although PPCM often strikes women with no obvious predisposition. Established risk factors include:

- Maternal age > 30–35 years: Older childbearing age has been linked with higher chance.
- Multifetal pregnancy: Twins or higher-order gestations impose greater hemodynamic stress and are associated with higher PPCM incidence.
- History of preeclampsia or hypertension: Hypertensive disorders of pregnancy (preeclampsia, gestational hypertension) are frequently noted in PPCM patients, suggesting overlapping pathophysiology (e.g. anti-angiogenic factors).
- Multiparity: Having multiple prior pregnancies (grand multiparity) may increase risk.
- Prolonged tocolysis: Long-term use of beta-agonists to prevent preterm labor has been suggested as a potential contributor in some cases (though evidence is not conclusive).

It is important to note that many women who develop PPCM have no identifiable risk factors. Genetic predisposition is emerging as an important factor – about 15–20% of PPCM patients harbor mutations in cardiomyopathy genes (most commonly truncating variants of the titin gene, also implicated in familial dilated cardiomyopathy). This overlap in genotype suggests that pregnancy may unmask a subclinical susceptibility in some women.

Given its potential severity and the need for timely therapy, PPCM demands early recognition. Any pregnant or postpartum woman presenting with unexplained shortness of breath, orthopnea, or other signs of heart failure should prompt consideration of PPCM, after excluding more common obstetric causes. Heightened awareness among obstetric and cardiac professionals, along with collaborative care (cardio-obstetrics teams), is vital to improve outcomes in this condition.

PATHOLOGY (PATHOGENESIS)

The pathogenesis of peripartum cardiomyopathy is complex and not yet fully elucidated. A multifactorial “two-hit hypothesis” is widely cited, wherein the physiologic stresses of late pregnancy act upon a background of genetic or acquired susceptibility to precipitate cardiomyopathy. Key elements proposed in the pathophysiology include:

- Hemodynamic stress of pregnancy: The peripartum period involves volume expansion, increased cardiac output, and hemodynamic fluctuations that can strain the myocardium. In most women this is well-tolerated, but in a susceptible heart it may lead to ventricular dilation and dysfunction.
- Hormone-induced cardiotoxicity: Prolactin – a pituitary hormone markedly elevated in the peripartum period – has been implicated as a central player. Under oxidative stress conditions, the 23-kDa prolactin hormone can be cleaved by cathepsin D into a 16-kDa fragment that is angiostatic and pro-apoptotic. This cleaved prolactin fragment causes endothelial dysfunction and impairs cardiomyocyte metabolism, leading to myocardial damage. Evidence supporting this comes from animal models where bromocriptine (which inhibits prolactin release) prevented PPCM-like heart failure, and small human studies showing improved recovery with bromocriptine therapy.
- Anti-angiogenic factors: There is significant overlap between PPCM and preeclampsia in terms of risk profile and timing, suggesting a shared mechanism involving placental factors. Soluble fms-like tyrosine kinase-1 (sFlt1), an anti-angiogenic protein elevated in preeclampsia, has also been found at high levels in some PPCM patients. sFlt1 and other placental hormones may contribute to microvascular dysfunction in the heart, reducing myocardial blood supply and contractility. The vascular insult caused by these factors during late pregnancy (“first hit”) could set the stage for myocardial failure when combined with peripartum hemodynamic stress.
- Autoimmune and inflammatory mechanisms: Pregnancy involves immune tolerance adaptations that may rebound postpartum. PPCM may, in part, represent a myocarditis or autoimmune process triggered after delivery. Myocardial biopsy studies have shown myocarditis in a subset of PPCM cases (inflammatory cells in 30–50% of samples in some series). Additionally, higher titers of cardiac autoantibodies (e.g. anti-myosin antibodies) have been detected in women with PPCM compared to idiopathic dilated cardiomyopathy. These findings raise the possibility that immune dysregulation or an autoimmune attack on the myocardium contributes to disease pathogenesis. In some patients, fetal microchimerism (persistence of fetal cells in maternal circulation) has been hypothesized to incite an immune reaction in the maternal heart after delivery, though the clinical significance of this remains speculative.
- Genetic predisposition: As noted, a substantial minority of PPCM patients have mutations in genes linked to dilated cardiomyopathy (e.g. TTN, MYH7, SCN5A, PSEN2, TNNT2). Carriers of these mutations may have

subclinical myocardial vulnerability. Pregnancy-induced physiological stress or hormonal effects could then trigger overt heart failure in these individuals. The overlap with familial cardiomyopathy suggests that PPCM is not a distinct entity in those cases but rather pregnancy acting as a trigger for phenotypic expression of an underlying cardiomyopathic process.

In summary, PPCM likely results from an interplay of vascular, hormonal, immune, and genetic factors. A plausible unifying model is that late pregnancy creates a high oxidative stress environment (due to high metabolic demand and relative vascular instability). In genetically susceptible or primed individuals, this leads to generation of toxic hormone metabolites (like the prolactin fragment) and release of anti-angiogenic factors, which in turn cause endothelial injury, myocarditis, and myocardial cell apoptosis. The result is acute systolic heart failure. Research is ongoing, and recent studies (such as investigations into microRNA profiles and metabolic signatures in PPCM) continue to shed light on potential molecular targets and biomarkers. Understanding these mechanisms is crucial, as it has already informed potential therapies (e.g. prolactin blockade) and may guide future preventive strategies or personalized treatments.

CLINICAL FEATURES

Presentation: The clinical presentation of PPCM mirrors that of acute heart failure, often occurring in an otherwise healthy-appearing peripartum woman. The onset is typically in the last month of pregnancy or within the first 4–5 months postpartum, with the majority of cases presenting in the early postpartum period (first 1–2 months after delivery). In fact, fewer than 10% of cases occur before delivery in some series. This timing can complicate recognition, as normal late pregnancy is associated with fatigue, mild dyspnea, and edema. However, the hallmark symptoms of PPCM are those of moderate to severe heart failure (often New York Heart Association class III–IV at diagnosis):

- **Dyspnea** – Shortness of breath on exertion is most common, and patients often note difficulty with activities that were previously well-tolerated. Orthopnea (needing to elevate the head to breathe comfortably while lying flat) and paroxysmal nocturnal dyspnea (waking up acutely short of breath) are red flags in the peripartum setting.
- **Excessive fatigue and exercise intolerance** – Beyond normal pregnancy tiredness, women may experience profound fatigue and inability to perform routine tasks.
- **Peripheral edema** – Swelling of the ankles and legs is common in late pregnancy, but in PPCM it is often more pronounced and may extend to sacral or abdominal edema. Rapid weight gain from fluid retention can

occur. Pulmonary edema may manifest as cough and orthopnea.

- **Chest discomfort or palpitations** – Some patients report chest tightness or pain (often due to heart strain or concomitant ischemia). Palpitations can occur due to tachycardia or arrhythmias (sinus tachycardia is common; atrial fibrillation or ventricular arrhythmias can also occur in severe cases).
- **Syncope or near-syncope** – If arrhythmias or very low cardiac output develop, patients might experience lightheadedness or fainting.

On physical examination, findings are those of acute decompensated heart failure:

- **Vital signs:** Tachycardia is common, and blood pressure may be normal or low (especially if cardiogenic shock is impending). In contrast to preeclampsia-related heart failure, severe hypertension is usually absent in PPCM (unless coexisting preeclampsia is present).
- **Pulmonary exam:** Rales or crackles in the lung bases indicate pulmonary edema. Oxygen saturation may be decreased in acute cases.
- **Cardiac exam:** There may be a displaced apical impulse (if the heart is enlarged) and often a third heart sound (S3 gallop) – a classic sign of systolic dysfunction. Regurgitant murmurs of the mitral or tricuspid valve might be heard, reflecting functional regurgitation due to dilated ventricles. Jugular venous distension can be observed in volume-overloaded patients.
- **Extremities:** Pitting edema in legs, and sometimes cold extremities if perfusion is poor. Hepatomegaly and ascites can appear in more advanced failure.

Importantly, neurologic or thromboembolic complications can sometimes be the presenting feature. PPCM creates a hypercoagulable state (due to low flow and peripartum changes), so intracardiac thrombi can form in severely dilated, akinetic left ventricles. This can lead to systemic emboli – for example, stroke or limb ischemia – as an initial manifestation in rare cases. Likewise, arrhythmias (ventricular tachycardia/fibrillation) may cause sudden cardiac arrest in PPCM patients, contributing to maternal mortality.

Because these clinical features overlap with other peripartum conditions, diagnostic vigilance is critical. Clues favoring PPCM over normal pregnancy changes include: orthopnea/PND, resting tachycardia out of proportion to fever or blood loss, an audible S3 gallop, and significant pulmonary crackles. Any suspicion should prompt further evaluation, as detailed below.

DIAGNOSIS

Diagnostic Criteria

PPCM is essentially a diagnosis of exclusion in a specific

clinical context. The classic diagnostic criteria include :

1. Onset of heart failure in the peripartum period: Specifically, heart failure symptoms developing in the last month of pregnancy or within 5 months postpartum. Most definitions encompass late-third-trimester through about 5 months after delivery as the window for PPCM onset.
2. Left ventricular systolic dysfunction on echocardiography: Typically defined as LVEF < 45% (or fractional shortening <30%), often with an enlarged left ventricular end-diastolic dimension (though dilation may not be present in all cases) .
3. No other identifiable cause of heart failure: No prior cardiac disease (e.g. valvular stenosis, congenital heart disease) or alternate cause such as myocardial infarction, severe hypertension, or toxic damage that can explain the cardiomyopathy.


In practice, a new mother meeting these criteria would be labeled as PPCM after excluding other diagnoses. The evaluation proceeds concurrently with management, given that PPCM is a diagnosis that requires urgent treatment. Key steps in diagnosis include:

- Clinical evaluation: A thorough history and physical exam to assess heart failure severity and look for clues of other etiologies. Important differentials to exclude are pulmonary embolism (can cause acute right heart failure and respiratory distress), amniotic fluid embolism (presents with sudden shock, DIC, and respiratory failure in immediate postpartum), acute myocardial infarction or coronary dissection (rare in young women, but pregnancy can precipitate spontaneous coronary artery dissection – SCAD), and hypertensive cardiomyopathy (severe preeclampsia or eclampsia can lead to acute pulmonary edema, but usually with markedly elevated BP). The ESC position statement specifically highlights PE, MI, and pregnancy-induced hypertensive heart disease as critical exclusions . A history of hypertension or chest pain might redirect the diagnosis towards those etiologies.
- Laboratory tests: While no blood test is diagnostic of PPCM, labs assist in ruling out other conditions and assessing severity. A B-type natriuretic peptide (BNP or NT-proBNP) is typically elevated in PPCM and can help distinguish cardiac dyspnea from normal pregnancy dyspnea . Cardiac troponin may be mildly elevated if myocardial injury is present, but high troponin would raise concern for acute coronary syndrome or severe myocarditis. Other routine tests include a complete blood count, electrolytes, renal and liver function, and thyroid function (postpartum thyroiditis can cause heart failure, though rarely this acute). Inflammatory markers (ESR, CRP) and viral titers might be checked if myocarditis is suspected. Importantly, preeclampsia

labs (e.g. liver enzymes, coagulation profile) should be checked if hypertension or other signs are present, to see if the heart failure is part of a multi-organ preeclampsia syndrome.

- Electrocardiogram (ECG): ECG may show sinus tachycardia, which is common but nonspecific. ST-T wave changes can occur; however, dramatic ischemic changes would prompt evaluation for acute MI. Arrhythmias like atrial fibrillation or frequent ventricular ectopics might be noted. A normal ECG does not rule out PPCM, but an abnormal ECG (e.g. ST elevations, Q waves) might point to ischemic causes.
- Imaging – Chest X-ray: A chest radiograph often shows cardiomegaly (enlarged cardiac silhouette) and pulmonary edema in PPCM. While not specific, it helps confirm heart failure (vascular congestion, pleural effusions) and can exclude lung pathologies like pneumonia. Chest X-ray can also hint at alternative diagnoses (e.g. signs of pulmonary embolism such as Westermark's sign or just a normal heart size in PE versus enlarged in cardiomyopathy).
- Imaging – Echocardiography: Transthoracic echocardiogram is the cornerstone of diagnosis. It will typically reveal a dilated left ventricle with global systolic dysfunction (reduced wall motion across all segments) and a decreased ejection fraction <45% . The degree of dilation can vary; some PPCM hearts are moderately enlarged, others have near-normal chamber size but poor contraction (a dilated phenotype is common, akin to dilated cardiomyopathy). Echocardiography also assesses right ventricular function, which may be impaired in PPCM as well. It is crucial for excluding other structural heart diseases: valves are usually normal aside from functional regurgitation, and there should be no significant congenital abnormalities. Intracardiac thrombus (often in the left ventricle apex) can sometimes be visualized in cases with very low EF. Doppler evaluation may show diastolic dysfunction and high filling pressures. The echo provides a baseline to monitor recovery or progression. Diagnostic criteria historically included a left ventricular end-diastolic higher than 2.7 cm/m² BSA , but contemporary definitions do not require a specific dimension as long as EF is reduced. Still, measuring dimensions and wall thickness is important for differentiating from other cardiomyopathies (e.g. hypertrophic cardiomyopathy, which would show increased wall thickness and different features).

Figures.



- Cardiac MRI: If echocardiographic findings are inconclusive or if myocarditis is strongly suspected, cardiac magnetic resonance imaging (CMR) can be valuable. CMR with gadolinium can identify myocardial fibrosis or inflammation. Late gadolinium enhancement patterns in PPCM are variable; some patients show a myocarditis pattern (subepicardial enhancement) while others may have nonspecific or no enhancement. MRI can also more sensitively detect intracardiac thrombi. However, MRI is usually done after delivery (gadolinium is contraindicated in pregnancy) and is not mandatory if echo already confirmed the diagnosis. Endomyocardial biopsy is not routinely done, but in cases of fulminant heart failure where giant cell myocarditis is in the differential, biopsy can be considered.

Ultimately, the diagnosis is confirmed when a peripartum onset cardiomyopathy is identified by echocardiography and no alternative cause is found. One must be cautious to exclude high blood pressure as the primary driver; for example, a woman with severe preeclampsia could develop heart failure with preserved EF (from diastolic dysfunction) or mild systolic dysfunction due to afterload stress – which is managed slightly differently. In PPCM, typically blood pressure is not extremely high, and the degree of LV systolic dysfunction is out of proportion to any hypertension.

Disease Severity and Monitoring: Once PPCM is diagnosed, initial severity is often stratified by standard heart failure classifications. Many patients present with acute decompensated HF requiring hospitalization. The New York Heart Association (NYHA) functional class is used to quantify symptoms (III = marked limitation, IV = symptoms at rest). Additionally, hemodynamic stability should be assessed. Markers of severity include very low LVEF (e.g. <30%), presence of cardiogenic shock (hypotension, end-organ hypoperfusion), significant RV failure, or arrhythmias. These

factors guide the intensity of treatment (e.g. need for ICU care or mechanical support).

Close monitoring is essential: daily weights, input/output, symptom tracking, and lab monitoring (renal function, electrolytes) are routine. Serial BNP levels can help track improvement. An echocardiogram is often repeated at 2–6 week intervals initially to gauge recovery or worsening. If there is poor improvement by 2–3 months postpartum, discussions about defibrillator placement or advanced therapies may be initiated (since by definition, by 6 months postpartum the “peripartum” window closes, and persistent cardiomyopathy would be considered chronic at that point).

TREATMENT

Management of PPCM revolves around standard heart failure therapy with careful consideration of the safety for mother, fetus, and breastfeeding infant, as well as the unique context of peripartum physiology. A multidisciplinary team – typically cardiology, maternal-fetal medicine (high-risk obstetrics), intensivists, and neonatology – should collaborate. Treatment strategies can be divided into: acute stabilization, guideline-directed medical therapy for heart failure, adjunctive therapies (including experimental), and long-term management and preventive measures.

Acute Stabilisation:-A: A woman presenting with acute heart failure near term or postpartum should be promptly stabilised:

- Hospitalisation:** is often required, especially for new-onset PPCM with significant symptoms. If respiratory distress is present (pulmonary edema) or oxygen saturation is low, supplemental oxygen and possibly ventilatory support (noninvasive positive pressure ventilation, or intubation in severe cases) may be needed.
- Diuresis:** Intravenous loop diuretics (e.g. furosemide) are administered to relieve pulmonary edema and peripheral edema. Diuretics must be used cautiously if the patient is still pregnant, as excessive volume reduction could compromise placental perfusion. However, in acute pulmonary edema, diuretics are life-saving and indicated.
- Vasodilator therapy:** If blood pressure is adequately maintained, vasodilators reduce afterload and improve cardiac output. In a pregnant woman, hydralazine plus nitrates is the preferred afterload reduction regimen (hydralazine is often used for hypertension in pregnancy, and nitrates like isosorbide dinitrate can be added) – this combination is safe in pregnancy and helps unload the failing heart, similar to how ACE inhibitors are used outside of pregnancy. In postpartum women, an ACE inhibitor (e.g. enalapril) or angiotensin receptor blocker (ARB) can be started once blood pressure tolerates, as these are first-line therapies for systolic heart failure.

ACE inhibitors are contraindicated during pregnancy (due to teratogenicity), but are recommended postpartum for PPCM if the mother is not breastfeeding (or even if breastfeeding, certain ACE-Is like enalapril are considered relatively safe with monitoring). ACE-I/ARB therapy improves survival and chances of recovery by reducing afterload and adverse remodeling.

- Inotropic support: For patients in cardiogenic shock (hypotension, end-organ damage), IV inotropes such as dobutamine or milrinone may be used to augment contractility temporarily. Dobutamine is typically preferred in pregnancy if needed, as it increases cardiac output. Milrinone (a phosphodiesterase-3 inhibitor) can also reduce afterload and improve output but may cause more vasodilation. These are usually short-term bridges. Caution: inotropes increase myocardial oxygen demand and arrhythmia risk, so they are used in ICU settings.
- Mechanical circulatory support: In cases where pharmacological therapy proves ineffective, early initiation of mechanical circulatory support should be considered due to the favorable prognosis for cardiac recovery in peripartum cardiomyopathy. (meaning a temporary support can sustain the patient to recovery). Options include intra-aortic balloon pump to improve coronary circulations and reduce afterload, venous-arterial ECMO (extracorporeal membrane oxygenation) for severe cardiac and respiratory failure, or Impella (a percutaneous LV assist device). In refractory cases, or if cardiogenic shock persists, implantation of a ventricular assist device (VAD) as a bridge to recovery or transplant may be necessary. PPCM is among the leading causes of peripartum cardiogenic shock requiring transplant or VAD in some series. Fortunately, only a small percentage of PPCM patients progress to needing long-term mechanical support or transplant (in the IPAC study, 4% required transplant or LVAD within one year).
- Delivery of the fetus: If the patient is pregnant and near term with unstable heart failure, a decision may be made to expedite delivery. Delivery (especially after 34+ weeks gestation) can alleviate volume load and allow more aggressive HF therapy (like ACE inhibitors postpartum). This decision is individualized: if the mother is in extremis or not responding to therapy, emergent delivery (often via C-section with appropriate anesthesia) may improve maternal hemodynamics. Otherwise, if the pregnancy is early or the mother stabilizes, it may be possible to continue the pregnancy under close monitoring.

Throughout acute management, continuous monitoring (telemetry for arrhythmias, frequent vitals) is needed. Thromboembolic prophylaxis with heparin is often initiated if there is severe LV dysfunction, as discussed below.

Heart Failure Pharmacotherapy

Once the patient is stabilized and especially in the postpartum period, standard heart failure medications form the backbone of therapy, aiming to improve cardiac function and halt disease progression. Many of these medications are continued for many months and tapered only if recovery is robust and sustained. Key pharmacotherapies include:

- ACE-I or ARB: These are first-line agents in HFrEF (heart failure with reduced EF) to reduce afterload and inhibit the renin-angiotensin system, thereby preventing adverse remodeling. In PPCM, ACE-I/ARBs are indicated post-delivery (e.g. enalapril, lisinopril, captopril are common; or valsartan as an ARB). They have been shown to improve LVEF and survival in PPCM as in other cardiomyopathies. During pregnancy, ACE-I/ARBs must be avoided (risk of fetal renal damage, oligohydramnios, skull abnormalities), so hydralazine/nitrates serve as substitutes. If blood pressure is low, initiation might be delayed until the patient is a bit more stable, but they should be started before hospital discharge if possible (postpartum).
- Beta-Blockers: These reduce sympathetic stress on the heart and improve survival in heart failure. metoprolol succinate or bisoprolol or carvedilol (non-selective beta and alpha blocker) is used in PPCM patients who are hemodynamically stable. Beta-blockers are relatively safe in pregnancy; indeed, many women with PPCM might already be on a beta-blocker if they had pregnancy hypertension (labetalol is commonly used for preeclampsia). In the heart failure context, beta-blockers are started at low dose after initial stabilization (not in acute pulmonary edema, but once diuresis has begun and the patient is out of shock). They are titrated up as tolerated. Beta-blockers help improve LVEF over time and reduce arrhythmia risk. One caution: in a fragile postpartum patient, beta-blockers can worsen fatigue and hypotension, so careful dose titration is needed.
- Diuretics: Loop diuretics (furosemide, bumetanide) and others (thiazides, aldosterone antagonists) are used to manage volume overload. Furosemide is often continued orally after IV diuresis. Spironolactone, an aldosterone antagonist, is a standard heart failure medication shown to improve outcomes in HFrEF. Spironolactone is contraindicated in pregnancy due to anti-androgenic effects on the fetus, but can be started postpartum if the patient is not breastfeeding (or with caution if breastfeeding, as small amounts can pass into milk). Diuretics will alleviate symptoms but must be balanced to avoid renal dysfunction or decreased perfusion. Patients are usually sent home with diuretics and advised on a low-salt diet and fluid restriction to prevent recurrent volume overload.

- Vasodilators (Hydralazine/Isosorbide dinitrate): If ACE-I/ARB are not tolerated (e.g. due to renal issues or persistent postpartum hypertension concerns) or during pregnancy, the combination of hydralazine and nitrates is a suitable alternative. This combo has proven mortality benefit in HFrEF, especially in black patients (A-HeFT trial in non-PPCM HF). Many PPCM patients will be on this if they developed cardiomyopathy antepartum. It remains part of therapy if needed for afterload reduction.
- Digoxin: Digitalis can increase the inotropy of the heart. Historically, digoxin was used in many PPCM cases to help augment cardiac output. However, modern practice is more reserved with digoxin unless needed for rate control in atrial fibrillation or persistent low-output state. Digoxin can be used in pregnancy and breastfeeding in low doses. Given its narrow therapeutic index and lack of proven mortality benefit, it is not routinely used unless specific indications (e.g. atrial fibrillation with rapid ventricular response, or symptomatic relief in persistent low EF despite other therapy).
- Anticoagulation: Patients with PPCM, particularly those with LVEF < 30–35%, are at increased risk of thrombosis in the left ventricle (due to blood stasis) and thromboembolism. Additionally, the hypercoagulable state of pregnancy/postpartum elevates risk. Anticoagulation is recommended in PPCM patients with severely reduced EF or evidence of intracardiac thrombus. If the patient is still pregnant, Enoxaparin or unfractionated heparin is used (warfarin is teratogenic in pregnancy). Postpartum, warfarin or DOACs (direct oral anticoagulants) can be used, but warfarin is often preferred especially if the patient is breastfeeding (DOACs safety in breastfeeding is not established; warfarin does not transfer significantly into breast milk). Bromocriptine therapy (discussed below) further necessitates anticoagulation, as bromocriptine has been associated with thromboembolic events. The duration of anticoagulation is typically at least until significant improvement in EF is documented or for 6–12 months. If a woman has persistent severe dysfunction, long-term anticoagulation may be advised.
- ARNI:- Sacubitril-valsartan has become standard in chronic HFrEF. There is limited data in PPCM specifically, but in a woman postpartum who remains symptomatic, switching ACE-I to ARNI could be beneficial to further improve remodeling. ARNIs are contraindicated in pregnancy and not tested in breastfeeding, so usage would be only in those definitively not pregnant and likely not nursing.
- Ivabradine: This sinus node inhibitor can reduce heart rate in patients who remain tachycardic despite beta-blockers. It's not first-line and not studied in PPCM particularly, but

could be considered off-label in refractory cases (and only postpartum, since safety in pregnancy is unknown).

Monitoring and Titration: The above medications are introduced carefully and uptitrated to target doses as tolerated, following heart failure guidelines. Blood pressure and renal function need monitoring as ACE-I/ARBs and diuretics can affect them.

Role of Bromocriptine (Prolactin Inhibition)

One of the most discussed emerging therapies in PPCM is bromocriptine, a dopamine D2 agonist that suppresses prolactin release from the pituitary. The rationale, as noted earlier, is to prevent formation of the toxic prolactin fragments implicated in PPCM pathogenesis. Bromocriptine is not yet standard of care in most countries but has been used extensively in research settings and in Germany/South Africa with promising results.

Key points on bromocriptine therapy:

- Evidence: A pilot study in 2010 (Sliwa et al., *Circulation*) in South Africa and a subsequent German randomized trial in 2017 (Hilfiker-Kleiner et al., *Eur Heart J*) suggested that adding bromocriptine (typically 2.5 MG. twice daily for 15 days, then daily for 1 month) to standard therapy improved LVEF recovery and clinical outcomes in acute severe PPCM. Patients receiving bromocriptine had higher rates of full recovery. These trials were relatively small, but the consistent positive signal led to incorporation of bromocriptine in European practice for severe cases. Currently, a larger international trial (REBIRTH) is underway to provide more definitive evidence.
- Use in practice: Given the existing data, bromocriptine is considered in patients with severe PPCM, especially those in cardiogenic shock or with EF <25% despite initial therapy. In such scenarios, the potential benefit in recovery might outweigh risks. Bromocriptine is usually given for 6–8 weeks. It requires halting breastfeeding, since it will dry up lactation by blocking prolactin. This is a significant consideration in counseling patients.
- Risks: Bromocriptine has been associated with thromboembolic complications (strokes, myocardial infarction) in postpartum women, likely because it further increases the propensity for clotting in an already hypercoagulable period. For this reason, full anticoagulation is mandatory when using bromocriptine. Typically, heparin or enoxaparin is started concurrently and continued through the bromocriptine course. Other side effects of bromocriptine include hypotension, headaches, and nausea.
- Guideline stance: The 2019 ESC Position Statement acknowledges bromocriptine as a potential therapy for PPCM, particularly recommending consideration of a

short course (one week high-dose followed by lower dose for 4–6 weeks) in patients with severe presentations. In some centers, a shorter 2-week course was tried with some success. U.S. guidelines (ACCF/AHA) have not formally incorporated bromocriptine due to lack of FDA indication and large-scale trial data, but expert consensus suggests it may be considered in life-threatening cases after informed consent. Thus, its use remains individualized.

Additional Therapies and Considerations

- **Immunosuppressive Therapy:** If endomyocardial biopsy demonstrates giant cell myocarditis or active lymphocytic myocarditis, immunosuppressive regimens (such as high-dose steroids and azathioprine) might be tried, though this is not standard for typical PPCM. For the majority of PPCM patients (even those with myocarditis on biopsy), routine immunosuppression has not shown clear benefit and is not recommended without a specific indication.
- **Mechanical Devices & ICD:** In patients who survive the acute phase but have persistently severely reduced EF (<35%) after 2–3 months, consideration is given to a wearable defibrillator (LifeVest) or implantable ICD to prevent sudden death. However, because PPCM often shows improvement, many clinicians prefer a wearable defibrillator for 6 months rather than immediately placing an ICD, unless there have been sustained ventricular arrhythmias. If after 6 months the EF remains <35%, an ICD for primary prevention is indicated similar to other non-ischemic cardiomyopathies. Conversely, if EF improves, ICD can be deferred (which is frequent in PPCM). Cardiac resynchronization therapy (CRT) may be considered if EF <35% and significant electrical dyssynchrony (left bundle branch block) persists, but again, not usually early on as recovery may obviate the need.
- **Monitoring and Follow-up:** Women with PPCM require close follow-up after initial treatment. Typically, an echocardiogram is repeated ~6–8 weeks postpartum, then at 3 months, 6 months, and 1 year to track recovery. Clinical follow-ups to adjust medications (titrating beta-blocker and ACE-I doses upward as tolerated) occur every few weeks in the early phase. Education on monitoring symptoms at home (daily weights, noting any increase in edema or nocturnal dyspnea) is important. Adherence to medication and dietary sodium restriction is reinforced.
- **Withdrawal of Therapy:** For those who achieve full recovery (EF back to normal $\geq 50\%$), the optimal duration of therapy is not well defined. Many experts continue HF medications for at least 12 months post-recovery. Some will then cautiously taper medications (perhaps stopping diuretics first if no longer needed, then ACE-I or beta-blocker) one at a time, monitoring for any drop in EF.

Others advocate continuing therapy longer (several years) given the risk of relapse. In any case, any subsequent pregnancy is usually discouraged or deferred (see below) because of relapse risk, so long-term tolerance of medications isn't typically an issue except for side effects.

Prognosis and Outcomes

With contemporary management, the outlook for PPCM has improved, but outcomes are heterogeneous:

- **Recovery:** A significant proportion of patients experience substantial improvement or normalization of ventricular function. In a North American cohort (IPAC study), 72% of women achieved an LVEF $\geq 50\%$ by 12 months postpartum with appropriate treatment. The most rapid gains in EF often occur in the first 2–6 months of therapy. Many patients who recover can eventually lead normal lives without heart failure symptoms.
- **Persistent cardiomyopathy:** Unfortunately, not all patients recover. In the IPAC study, 13% had persistent severe cardiomyopathy (EF <35%) or died or needed transplant within one year. Other studies have shown chronic heart failure symptoms in 20–30% of patients despite some EF improvement. Factors associated with incomplete recovery include very low EF at presentation (<30%), very enlarged LV dimensions, late diagnosis (more weeks postpartum before treatment initiation), and African American race. These high-risk features can be identified early; for instance, women who present with EF <20% and requiring ICU care have a guarded prognosis and should be considered for advanced therapies promptly.
- **Mortality:** Maternal mortality due to PPCM varies by region. In the U.S., short-term mortality is on the order of 5–10%. Most deaths occur in the first few months (often from arrhythmic sudden death or pump failure). In regions like sub-Saharan Africa, 6-month mortality can be ~15% and 2-year mortality up to 28%, reflecting later presentation and limited access to advanced therapies. Access to heart transplantation can be lifesaving for those who fail to recover (PPCM is a reason for about 4% of transplants in women of childbearing age).
- **Thromboembolism and Arrhythmias:** These complications contribute to morbidity. Strokes, systemic emboli, or pulmonary emboli can occur, especially if no anticoagulation was given in a patient with low EF. Arrhythmias (atrial fibrillation, non-sustained VT, etc.) are observed in a significant subset and can cause symptoms or even mortality (sudden death from VF). Thus monitoring and prophylactic measures (anticoagulation, beta-blockers, possibly ICD for high-risk) are important parts of management to improve outcomes.

CONCLUSION

Peripartum cardiomyopathy is an uncommon yet serious complication of pregnancy that necessitates heightened clinical vigilance and prompt, assertive intervention. It represents a unique intersection of cardiology and obstetrics, wherein heart failure develops in otherwise healthy young women at a fragile time around childbirth. Early diagnosis and prompt initiation of therapy are critical and have been shown to improve outcomes. Echocardiographic screening of women with significant peripartum symptoms has been advocated in high-risk populations to avoid delays in care.

The mainstay of treatment is guideline-directed heart failure therapy (diuretics, beta-blockers, ACE inhibition, and supportive care), tailored to the context of pregnancy and postpartum safety. In recent years, the recognition of prolactin's role has opened a potential targeted therapy in the form of bromocriptine, which, while not universally adopted, illustrates how mechanistic insights can lead to novel interventions. Importantly, most women with PPCM do have the potential for full cardiac recovery, especially with comprehensive care – a feature that distinguishes PPCM from many other cardiomyopathies. This propensity for recovery means that temporary aggressive measures (such as mechanical support) are often justified, and many patients can be bridged through the acute phase to a good long-term outcome. Indeed, PPCM can paradoxically have a better prognosis than idiopathic dilated cardiomyopathy, provided it is recognized and treated expeditiously.

However, PPCM remains a major contributor to maternal morbidity and mortality worldwide. Awareness and education are key: obstetricians, midwives, emergency physicians, and primary care providers must be aware that new-onset heart failure in late pregnancy is an emergency requiring cardiology input. The establishment of multidisciplinary Cardio-Obstetrics teams in many centers is a positive development to coordinate such care.

From a preventive standpoint, risk factor management is essential. Women with hypertension or preeclampsia should be closely monitored; controlling blood pressure and prompt delivery when indicated may mitigate cardiac stress. Avoidance of unnecessary tocolysis and counseling women on healthy pregnancy spacing and prenatal care may also reduce risk.

A critical aspect of PPCM management is counseling about future pregnancies. Subsequent pregnancy poses a significant risk of relapse of cardiomyopathy – the single strongest predictor of relapse is whether cardiac function fully normalized after the first episode. Women whose EF remains depressed (even moderately, say 40–50%) are generally advised against future pregnancy due to high ($\geq 50\%$) risk of recurrent HF and possible death. Even in women who recover

normal EF, there is an estimated 20–30% chance of recurrence of PPCM in a subsequent pregnancy. Those who do attempt another pregnancy must do so under close supervision: preconception cardiac evaluation (ensuring EF ideally $\geq 50\%$), switching to pregnancy-safe medications well in advance (e.g. stopping ACE-I/ARBs at least 3 months prior), and monitoring each trimester with echocardiograms. Delivery should be in a tertiary care center with a heart team available. In many cases, if the risks are deemed too high, permanent contraception (such as tubal ligation) is recommended as part of the long-term plan.

Looking ahead, ongoing research is aiming to refine risk stratification, such as identifying which genetic mutations portend worse outcomes, or whether biomarkers (like prolactin levels, microRNAs, or soluble Flt1) could enable earlier diagnosis even before overt symptoms. There is also interest in preventive therapy for very high-risk individuals (for example, some have proposed low-dose bromocriptine prophylaxis immediately postpartum in women with severe preeclampsia to prevent PPCM, though this remains experimental).

In conclusion, PPCM exemplifies a condition where vigilance and multidisciplinary care can turn a potentially fatal scenario into one of recovery and restored health. As our understanding of its pathophysiology grows, it is hoped that targeted treatments and preventive measures will further improve the outlook for women affected by this uncommon yet pivotal disease. Continued international collaboration and research are essential, given the relatively low incidence but high impact of PPCM on mothers and families. By adhering to current guidelines and individualized patient-centric care, clinicians can maximize the chances of a favorable outcome – enabling many women with PPCM to resume normal lives and motherhood, while navigating future pregnancies with caution and expert guidance when applicable.

REFERENCES

1. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the ESC Study Group on PPCM. *Eur J Heart Fail*. 2019;21(7):827–843.
2. Davis MB, Arany Z, McNamara DM, et al. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;75(2):207–221.
3. Carlson S, Trankle CM, Kessler K, et al. Peripartum Cardiomyopathy: Risks, Diagnosis, and Management. *Int J Women's Health*. 2023;15:89–99. Published 2023 May 9.

4. McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America (IPAC Study). *J Am Coll Cardiol*. 2015;66(8):905–914.
5. Hilfiker-Kleiner D, Haghighi A, Nonhoff J, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. *Eur Heart J*. 2017;38(35):2671–2679.
6. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. *Circulation*. 2010;121(13):1465–1473.
7. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. *Am J Cardiol*. 2007;100(2):302–304.
8. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. *N Engl J Med*. 2001;344(21):1567–1571.
9. Ford ND, Cox S, Ko JY, et al. Hypertensive disorders in pregnancy and mortality at delivery hospitalization — United States, 2017–2019. *MMWR Morb Mortal Wkly Rep*. 2022;71(17):585–591.
10. American Heart Association. Peripartum Cardiomyopathy (PPCM) – What is peripartum cardiomyopathy? [Internet]. Available from: <https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/peripartum-cardiomyopathy-ppcm>. Last reviewed May 28, 2024.
11. “Abstracts”, *European Journal of Heart Failure*, 2016.
12. Viviana Aursulesei, Mihai Dan. “Chapter 31” Peripartum Cardiomyopathy: A Systematic Review”, IntechOpen, 2012.
13. www.ncbi.nlm.nih.gov.
14. clinicalgate.com.
15. Rafid Fayadh. “Chapter 1 Clinical Presentation”, IntechOpen, 2011.